Search by Drug Name or NDC
NDC 61919-0917-30 ZONISAMIDE 100 mg/1 Details
ZONISAMIDE 100 mg/1
ZONISAMIDE is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Direct_Rx. The primary component is ZONISAMIDE.
MedlinePlus Drug Summary
Zonisamide is used in combination with other medications to treat certain types of seizures. Zonisamide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 61919-0917-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Zonisamide
Product Information
| NDC | 61919-0917 |
|---|---|
| Product ID | 61919-917_0e993203-3e8b-5fbd-e063-6294a90a0636 |
| Associated GPIs | 72600090000120 |
| GCN Sequence Number | 045100 |
| GCN Sequence Number Description | zonisamide CAPSULE 100 MG ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 92219 |
| HICL Sequence Number | 021140 |
| HICL Sequence Number Description | ZONISAMIDE |
| Brand/Generic | Generic |
| Proprietary Name | ZONISAMIDE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ZONISAMIDE |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | ZONISAMIDE |
| Labeler Name | Direct_Rx |
| Pharmaceutical Class | Anti-epileptic Agent [EPC], Carbonic Anhydrase Inhibitors [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], P-Glycoprotein Inhibitors [MoA], Sulfonamides [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA077634 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 61919-0917-30 (61919091730)
| NDC Package Code | 61919-917-30 |
|---|---|
| Billing NDC | 61919091730 |
| Package | 30 CAPSULE in 1 BOTTLE (61919-917-30) |
| Marketing Start Date | 2019-08-19 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |